PTG 300

Drug Profile

PTG 300

Alternative Names: PTG-300

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protagonist Therapeutics
  • Class Antianaemics; Peptides
  • Mechanism of Action Hepcidin-replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Beta-thalassaemia

Most Recent Events

  • 07 Aug 2018 Protagonist plans to file other regulatory submissions to support the initiation of a global phase II trial in patients with Beta-thalassemia
  • 30 Jun 2018 Protagonist Therapeutics files an IND application with the US FDA for Beta-thalassemia
  • 14 Jun 2018 Pharmacodynamics data from a preclinical study in Beta-thalassaemia presented at the 23rd Congress of the European Haematology Association (EHA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top